PhaseBio Pharmaceuticals to Participate in Upcoming Investor Conferences
February 26 2021 - 4:05PM
Business Wire
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of novel therapies for cardiopulmonary diseases,
today announced that the company will be participating in two
upcoming virtual investor conferences. Details of the events are as
follows:
- Cowen 41st Annual Health Care Conference Date: March 4,
2021 Time: 1:30 pm – 2:30 pm ET Chief Executive Officer,
Jonathan P. Mow, is scheduled to participate in a panel
discussion
- H.C. Wainwright Global Life Sciences Conference Date:
March 9, 2021 Time: On demand beginning at 7:00 am ET Chief
Executive Officer, Jonathan P. Mow, will present a company
overview
Interested parties can access the live and archived webcasts of
the virtual sessions on the “Events and Presentations” page of the
“Investors” section of the company’s website at www.phasebio.com.
The webcast replays will be available for 90 days after the
conclusion of the live presentations.
About PhaseBio
PhaseBio Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of novel therapies for cardiovascular and
cardiopulmonary diseases. The company’s pipeline includes:
bentracimab (PB2452), a novel reversal agent for the antiplatelet
therapy ticagrelor; pemziviptadil (PB1046), a once-weekly
vasoactive intestinal peptide receptor agonist for the treatment of
pulmonary arterial hypertension; and PB6440, an oral agent for the
treatment of resistant hypertension. PhaseBio’s proprietary
elastin-like polypeptide technology platform enables the
development of therapies with potential for less-frequent dosing
and improved pharmacokinetics, including pemziviptadil, and drives
both internal and partnership drug-development opportunities.
PhaseBio is located in Malvern, PA, and San Diego, CA. For more
information, please visit www.phasebio.com, and follow us on
Twitter @PhaseBio and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210226005652/en/
Investor Contact: John Sharp PhaseBio Pharmaceuticals,
Inc. Chief Financial Officer (610) 981-6506
john.sharp@phasebio.com
Media Contact: Will Zasadny Canale Communications, Inc.
will.zasadny@canalecomm.com (619) 961-8848
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Mar 2024 to Apr 2024
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Apr 2023 to Apr 2024